NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 59.32

+2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (321)	6/10/2010 10:38:36 AM
From: david nordic	1 Recommendation Read Replies (1) of 507

No doubt Gleevec works for CML - controls the white blood cell count. Mother in law was on it. NKTR 102 (Peg Irinotecan) has responses for many cancer types. NKTR 102 is in studies for Ovarian, Breast, Colon, replacement for Irinotecan in 5fu for starters. Avastin for Ovarian Cancer response was 16% Recist. NKTR 102 was 29% Recist Typical range is (6.5-13.8)for Single cancer agent. Survival is beyond 18 months currently in which death occurs within 3-5 months. Trial is continuing for 6 months extension. Keep it on your radar screen.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next